February 6, 2018 09:24 AM EST
R&D

Eye­ing a block­buster mi­graine mar­ket, Al­ler­gan takes an in­side track on acute cas­es with pos­i­tive PhI­II

John Carroll

Editor & Founder

With a full slate of in­jectable CGRP mi­graine drugs po­si­tion­ing them­selves at the fin­ish line for FDA ap­provals for chron­ic cas­es, Al­ler­gan $AGN to­day took …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times